search

Active clinical trials for "Leukemia, Myeloid, Acute"

Results 1911-1920 of 2320

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine,...

LeukemiaFLT3-Mutated Acute Myeloid Leukemia1 more

The goal of Part 1 of this clinical research study is to learn if ponatinib alone can help to control FLT3-mutated AML or FLT3-mutated high-risk MDS. The safety of this drug will also be studied. The goal of Part 2 of this clinical research study is to find the highest tolerable dose of ponatinib in combination with 5-azacytidine and to learn if the highest dose level found can help to control FLT3-mutated AML or FLT3-mutated high-risk MDS. The safety of this combination will also be studied.

Withdrawn32 enrollment criteria

Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation...

Acute Myelogenous LeukemiaGraft Versus Host Disease5 more

The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from an unrelated donor. This trial is designed to test the hypothesis that elimination of methotrexate in the unrelated donor group would lead to less transplant-related toxicity while still preserving the effective control of GVHD.

Completed21 enrollment criteria

Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study...

LeukemiaMyelocytic3 more

This trial is in high risk patients to determine the safety and efficacy of posaconazole vs. fluconazole in the prophylaxis against development of invasive fungal infections. Profound, prolonged neutropenia (Absolute neutrophil count<500 cells/cubic mm for at least 7 days) due to induction chemotherapy for acute myelogenous leukemia, or myelodysplastic syndrome. Treatment Duration: maximum of 12 weeks Follow-Up 2 months. Endpoints: incidence of proven or probable IFI according to EORTC/MSG criteria within the neutropenic episode and within 100 days of randomization as determined by external expert review.

Completed12 enrollment criteria

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia...

Leukemia

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Combining more than one chemotherapy drug with biological therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, isotretinoin, and interferon alfa in treating patients who have acute myelogenous leukemia.

Withdrawn3 enrollment criteria

Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease...

Acute Myeloid LeukemiaMinimal Residual Disease Negativity

This phase II trial studies how well autologous stem cell transplant works in treating patients with favorable or intermediate risk, minimal residual disease (MRD)-negative, acute myeloid leukemia. Giving chemotherapy before a peripheral blood stem cell transplant helps kill any cancer cells that are in the body. After treatment, stem cells are collected from the patient's blood and stored. Higher dose chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.

Withdrawn16 enrollment criteria

Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective...

Acute Myeloid Leukemia

Newly diagnosed adults patients with Acute Myeloid Leukemia will be assessed as traditionally by the treating institution using classic clinical, demographic and cytogenetic variables. Complementary molecular tests will be performed in the patients included in the study using PCR to detect classic CBF (Core Binding Factor) rearrangements: CBFB-MYH11 [inv(16)(p13;q22), isoforms A, E and D; AML-ETO (RUNX1-RUNX1T1) (t8;21)(q22;q22). NGS (Next Generation Sequencing) to detect mutations in: FLT3-ITD and TKD, NPM1, CEBPA, RUNX1, TP53, ASXL1, IDH1, IDH2 and KIT

Not yet recruiting8 enrollment criteria

Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56...

Acute Myeloid Leukemia

estimation of the clinical characters and out come of adult acute myeloid leukemia patients • correlation of the estimated clinical characters and outcome to the expression of CD200

Not yet recruiting6 enrollment criteria

Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

Acute Myeloid LeukemiaLeukemia1 more

This study will explore how malnutrition (poor nutrition/diet) and sarcopenia (a condition that causes a loss of muscle and bone mass) affects study participants over the age of 60 with acute myeloid leukemia (AML) who will receive induction chemotherapy (chemotherapy given as the first treatment to help cancer go into remission) and/or cancer drugs as part of standard care for AML. By studying how these nutritional and skeletal factors, doctors leading this study hope to learn how malnutrition and sarcopenia may be able to predict certain outcomes --such as how long study participants with poor nutrition and muscle loss can live after chemotherapy- for older (age 60+) individuals with AML.

Not yet recruiting7 enrollment criteria

Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for...

Acute Myelogenous LeukemiaAcute Lymphoid Leukemia4 more

The purpose of this study is to determine whether cyclophosphamide post bone marrow transplant increases the rate of patients alive, in remission and without immunosuppression, one year after transplant, when compared with the combination of methotrexate and calcineurin inhibitor

Terminated13 enrollment criteria

Frequency and Risk Factors of Acute Myeloid Leukemia

Myeloid Leukemia

to assess the frequency of acute myeloid leukemia at clinical Haematology unit of Assiute university hospital to study correlations of known risk factors and if there are new risk factors participate in increasing frequency of acute myeloid leukemia

Not yet recruiting2 enrollment criteria
1...191192193...232

Need Help? Contact our team!


We'll reach out to this number within 24 hrs